Oncology
F. Hoffmann-La Roche AG funds a broad oncology portfolio spanning breast cancer, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, colorectal cancer, and urothelial carcinoma, with additional activity in lymphoma, multiple myeloma, and other solid tumours.
- Breast cancer
- Non-small cell lung cancer
- Lymphoma
- Hepatocellular carcinoma
- Urothelial carcinoma
Its oncology research also includes biomarker-defined disease groups such as HER2-positive, hormone receptor-positive, PIK3CA-mutated, KRAS G12C-mutated, and ALK-rearranged cancers.
Neurology
The sponsor maintains strong interest in neurological disease, particularly multiple sclerosis across relapsing, progressive, and primary progressive forms, as well as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Angelman syndrome, and spinal muscular atrophy.
- Multiple sclerosis
- Alzheimer’s disease
- Parkinson’s disease
- Huntington’s disease
- Spinal muscular atrophy
Research also extends to neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and autoimmune encephalitis.
Immunology and Inflammatory Disease
Roche supports studies in rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, Crohn’s disease, ulcerative colitis, atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Crohn’s disease
- Ulcerative colitis
- Atopic dermatitis
Additional work covers thyroid eye disease, IgA nephropathy, primary membranous nephropathy, and paroxysmal nocturnal hemoglobinuria.
Ophthalmology and Vision Disorders
The sponsor is active in ophthalmology, with trials in neovascular age-related macular degeneration, choroidal neovascularization secondary to pathologic myopia, uveitic macular edema, and thyroid eye disease.
- Neovascular age-related macular degeneration
- Uveitic macular edema
- Choroidal neovascularization
- Thyroid eye disease
- Visual function
These studies include conditions affecting retinal and orbital inflammation, with attention to preserving visual acuity and related ocular outcomes.
Hematology, Metabolic, and Rare Diseases
Roche also funds research in hemophilia A, sickle cell disease, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and selected kidney diseases such as primary IgA nephropathy and lupus nephritis.
- Hemophilia A
- Sickle cell disease
- Paroxysmal nocturnal hemoglobinuria
- Atypical hemolytic uremic syndrome
- Primary IgA nephropathy
Its broader programme includes obesity, type 2 diabetes mellitus, hepatic impairment, and studies in healthy volunteers to support development across therapeutic areas.
